Search

Displaying results 2341 - 2350 of 10000 in total
  1. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  2. Drug

    Imgatuzumab

    go.drugbank.com/drugs/DB14884
    Investigational

    Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With

  3. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.

    Categories: MATE 1 Substrates, MATE 2 Substrates
  4. Drug

    Pegilodecakin

    go.drugbank.com/drugs/DB15162
    Investigational

    Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small

    Synonyms: INTERLEUKIN 10 (SYNTHETIC HUMAN), DIMER, N-TERMINAL 5-KILODALTON PEGYLATED
  5. Drug

    Celecoxib

    go.drugbank.com/drugs/DB00482
    ApprovedInvestigational

    [A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. … Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other

    Categories: Cyclooxygenase-2 (COX-2) Inhibitors, COX-2 InhibitorsSynonyms: p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
  6. Drug

    Haemagglutinin-strain B (Victoria-like)

    go.drugbank.com/drugs/DB15473
    Approved

    Mixtures: Afluria Tetra Injektionssuspension in einer FertigspritzeSynonyms: Haemagglutinin-strain B (Victoria), Haemagglutinin-strain B (Victoria-like)
  7. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking … [A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea.

    Categories: Topoisomerase II Inhibitors, P-glycoprotein inhibitors
  8. Drug

    Penicillamine

    go.drugbank.com/drugs/DB00859
    ApprovedInvestigational

    Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). … It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: (S)-2-amino-3-mercapto-3-methylbutanoic acid, D-β,β-dimethylcysteine
  9. Drug

    Depulfavirine

    go.drugbank.com/drugs/DB18890
    Investigational

    Depulfavirine is under investigation in clinical trial NCT05204394 (Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2nrtis From the 1st Line Standard of Care Therapy).

    Synonyms: 2-[4-Bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide, Benzeneacetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluoro-
  10. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. … In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.

    Synonyms: IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMER, IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMERProducts: TYSABRI®, TYSABRI® SUBCUTÁNEO 150MG/ML